证券日报网讯12月30日，瑞立科密（001285）在互动平台回答投资者提问时表示，随着境外客户开拓力 度的加强及合作关系的加深，公司境外销售收入占主营业务收入比重趋于提升，公司2024年境外销售收 入31172.91万元，占主营业务收入比重约为16%。 ...

（文章来源：证券日报） 证券日报网讯 12月19日，金力永磁在互动平台回答投资者提问时表示，12月18日商务部新闻发言人表 示"目前已收到并批准了部分中国出口商提交的通用许可申请"。公司也关注到"金力永磁及另外两家企 业已获得首批通用许可证"的相关媒体报道，对此公司不予置评，请以国家相关部门发布的信息为准。 2025年前三季度，公司实现境外销售收入9.42亿元，与上年同期基本持平；其中对美国出口的销售收入 为3.54亿元，同比增长43.92%。 ...

Core Viewpoint - Haofan Bio (301393) reported that its overseas sales revenue for 2024 is projected to account for 22.13% from Asia, 10.04% from Europe, and 4.09% from America of the total operating revenue [1] Group 1: Company Overview - The main products of the company are specialty chemical raw materials primarily based on peptide synthesis reagents, positioned upstream in the pharmaceutical industry chain [1] - The company offers a wide range of products and serves thousands of customers annually, demonstrating strong risk resistance capabilities [1] Group 2: Market Expansion - The company established a wholly-owned subsidiary in Germany in January 2025, targeting CDMO and formulation clients in the European market to further expand its business in Europe [1]